Tuesday, 9 November, 2004 - 21:00
Resonance Health Ltd - 03-Nov-04
Lodged response to ASX query.
Resonance Health, a healthcare technology and services company, engages in the development and commercialisation of magnetic resonance imaging (MRI) related technology primarily in Australia.
The company’s core product is FerriScan, a non-invasive liver diagnostic product used for the measurement of iron levels in the liver. Its FerriScan also provides a range of value added services for clinical trials using imaging end points.
The company is also developing imaging tools for the non-invasive assessment of liver fat and liver fibrosis to address clinical need for patients with fatty liver disease and viral hepatitis.
Rank | Company | 1 Yr | 5 Yr |
---|---|---|---|
946th | Maxxia | -7.63% | 7.32% |
947th | OFX Group | -7.67% | 0.09% |
948th | Resonance Health | -7.69% | -21.79% |
949th | CAQ Holdings | -7.69% | 0.85% |
950th | Endeavour Group | -7.71% | 0% |
Rank | Company | # | |
---|---|---|---|
95th | ![]() |
Resonance Health | $8.67m |
98th | ![]() |
DTI Group | $7.76m |
99th | ![]() |
FBR | $7.65m |
100th | ![]() |
Pointerra | $7.60m |
101st | ![]() |
RBR Group | $7.59m |
![]() |
RANKING: 26 Up from 28 in Technology Companies list | 22 Jan 2025 |
![]() |
RANKING: 32 Down from 28 in Technology Companies list | 10 Dec 2024 |
![]() |
RANKING: 28 Down from 27 in Technology Companies list | 04 Sep 2024 |
![]() |
NEWS: Tagged in Resonance to expand TrialsWest sites | 08 Aug 2024 |
![]() |
NEW ROLE: AS Pervez, | 01 Jul 2024 |
![]() |
NEWS: Tagged in Resonance acquires TrialsWest | 02 Apr 2024 |
![]() |
RANKING: 27 Up from 28 in Technology Companies list | 19 Feb 2024 |
Perth-based Resonance Health Ltd has gained independent international validation for its FerriScan liver treatment.
Nedlands-based Resonance Health Ltd has announced it has been granted Canadian regulatory clearance by Health Canada for FerriScan, its novel non-invasive diagnostic test for liver iron concentration.
Claremont based healthcare company Resonance Health Ltd today announced a deeply discounted $3.06 million entitlements offer at two cents per share to fund further development of FibroScreen, a non-invasive liver fibrosis test.
Advises that 33,500,008 Ordinary Shares will be released from voluntary escrow today.
CLAREMONT-BASED healthcare company Resonance Health Ltd this week announced a deeply discounted $3.06 million entitlements offer at two cents per share to fund further development of FibroScreen, a non-invasive liver fibrosis test using magnetic resonance imaging.
Resonance Health Limited has received an interim stop order from ASIC due to concerns over estimated research and development costs and cash flow assumptions.
Claremont-based magnetic resonance imaging technology developer Resonance Health Ltd has extended the distribution deal for its liver iron monitoring device FerriScan with Switzerland-based Novartis AG, the company has announced.
As a boy, Tim St Pierre loved playing with his magnets; now he’s a physics professor who is passionate about linking physics and biology through magnetic resonance imagery.
FEATURE: The state’s biotechnology sector is heating up as investors look for the next wave of investment opportunities amid waning resources investment.
Resonance Health intends to raise up to $5.1 million with a placement and entitlement offer, pitched at 5 cents per share.
Improving the diagnosis and management of patients with fatty liver conditions was the motivation for the 2014 WA Innovator of the Year winner, Resonance Health.
Local biotech firm Sun Biomedical has announced plans to buy Melbourne-based Dimerix Bioscience in exchange for a share package worth about $8.3 million.
The WA winners in the 2015 EY Entrepreneur of the Year awards are looking well beyond their home state for growth opportunities.
Medical technology may have taken a back seat to resources stocks during the mining boom, but the sector has generated a lot more interest of late, with several players in reverse takeovers on the ASX.
The search is on again for local innovators and entrepreneurs to participate in the 10th anniversary of the WA Innovator of the Year program.
Shares in Resonance Health jumped 53 per cent today after its FerriScan technology was recommended for use under a new set of medical guidelines in the UK.
Newly established Perth company OncoRes Medical has secured up to $6 million of funding to commercialise a surgical tool developed by researchers at the Harry Perkins Institute of Medical Research and the University of Western Australia.
Tony Howarth has resigned from the board of MMA Offshore. He was chair from 2006 to October 2017.
Scott Waddell has resigned as chief financial officer and company secretary of Metro Mining. Duane Woodbury has been appointed interim chief financial officer and Amy Treble takes over as company secretary in addition to her role as financial controller.
Shares in Resonance Health have doubled today after its FerriSmart technology, which uses machine learning to quantify liver iron concentration, received FDA approval.
Machine learning could enable major advances in healthcare, expanding the power of the medical sector to spot problems early.
Our board moves wrap includes Geoff Goldsmith, Giuseppe Di Franco, Andrew Lane, Nick Allan, Agha Shahzad, Mitchell Wells, Christian Viguie, Nicolas Clerc, and Martin Bennett.
Our board moves wrap includes Michael Tomasz, Hugh Callaghan, Jamie Myers, Alison Laws, Mitchell Wells, Ben Wyatt, Ian Tan-Kang, Darren Holden, and Ian Murray.
Several exciting AI innovations are emerging from WA, and the world is watching.
Our board moves wrap includes Walter Joseph, Heng Fai Chan, Blair Michelson, Mitchell Wells, Demetrios Pynes, Mauro Piccini, Jeremy King, Peter Wall, and Andrew Frazer.
Our weekly appointments wrap includes Meriel Steadman, Ben Gargett, Krista Bates, Emma Ramage, Christina Matthews, John Olynyk, Cathy Falkiner, Rob Scott, Mike Henry, Matt Comyn and Jeremy Taylor.
Resonance Health will enter the Chinese market after being contracted by Chinese pharmaceutical company Hangzhou Zede Pharma-Tech Co.
Our board moves wrap includes Andrew Metcalfe, George Lazarou, María Claudia Pohl Ibáñez, Christopher Chalwell, Michael Winlo, Brett Crowley, Erlyn Dawson, and Aaron Brinkworth.
Our board moves wrap includes Andrew Harrison and Mitchell Wells.
Our board moves wrap includes Sonu Cheema, Steve Samuel, Michelle Guthrie, Rowan Harland, Arron Canicais, Nick Woolrych, Patrick Holywell, and Nick Allan.
Healthcare tech and services company Resonance Health has won a $6.33 million contract from a multinational pharmaceutical company, subject to clinical trial approvals.
Our board moves wrap includes Kristie Young, Andrew Strickland, Jonathan Downes, Josh Merriman, Catherine Grant-Edwards, Melissa Chapman, Melissa North, Liesl Ellies, Patrick O'Connor, Sonu Cheema, Matthew Foy, and Guy Debelle.
Our weekly appointments wrap includes David Coyne, Lisa Wynne, Jérôme Pécresse, Neil Brodie, Benjamin Carruthers, Ash Colmer, Fiona Payne, Trent Barlett, Stephen Butcher, Rosemarie Myers, Clare Cullen and Paul Lyons.
Resonance Health has acquired TrialsWest in a consideration package worth up to $8 million.
Burswood-based Resonance Health has announced it will open a second TrialsWest facility in WA to provide better access to clinic trials, after acquiring the company in April.
Access to our data for Resonance Health is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Resonance Health is included in 2 lists - Technology Companies and Public Companies - Industrial WA.
For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.